STAT+: FDA Biosimilar Pathway, Trump Drug Costs

More Affordable Biologic Drugs on the Horizon: FDA Streamlines Approval Process

Washington, D.C. – On October 29, 2025, the food and Drug Management (FDA) unveiled a draft framework designed to accelerate the availability of more affordable biologic drugs to patients. The initiative aims to lower healthcare costs and increase access to life-changing medications.

The core of the plan involves streamlining the approval pathway for biosimilars – essentially copycat versions of already-approved biologic drugs.Currently, the clinical trials required to demonstrate a biosimilar’s similarity to the original biologic are extensive and costly. The FDA’s proposed framework seeks to reduce these clinical standards, thereby lowering the financial burden on manufacturers and shortening the time it takes to bring these alternatives to market.